Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

NCT01660451 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

227

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG: Copanlisib (Aliqopa, BAY80-6946)

Sponsor

Bayer